In Mouse Model, Combination Therapy Shows Potent Tumor Growth Inhibition
 

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, being held Nov. 12-16, 2011...

More...